"10.1371_journal.pone.0143800","plos one","2015-12-03T00:00:00Z","Corinne Klop; Paco M J Welsing; Hubert G M Leufkens; Petra J M Elders; Jetty A Overbeek; Joop P van den Bergh; Johannes W J Bijlsma; Frank de Vries","Utrecht Institute for Pharmaceutical Sciences, Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht University, Utrecht, Netherlands; Department of Rheumatology and Clinical Immunology, University Medical Center, Utrecht, Netherlands; Julius Center for Health Sciences and Primary Care, University Medical Center, Utrecht, Netherlands; Department of General Practice and Elderly Care, VU University Medical Centre, Amsterdam, Netherlands; PHARMO Institute for Drug Outcomes Research, Utrecht, Netherlands; Department of Internal Medicine, Viecuri Medical Centre, Venlo, Netherlands; Department of Internal Medicine, Maastricht University Medical Centre+, Maastricht, Netherlands; Biomedical Research Institute, University Hasselt, Hasselt, Belgium; Department of Clinical Pharmacy and Toxicology, Maastricht University Medical Centre+, Maastricht, Netherlands; MRC Lifecourse Epidemiology Unit, Southampton General Hospital, Southampton, United Kingdom","Conceived and designed the experiments: CK PMJW HGML PJME JAO JPvdB JWJB FV. Performed the experiments: CK. Analyzed the data: CK. Contributed reagents/materials/analysis tools: CK FV. Wrote the paper: CK. Reviewed the manuscript: PMJW HGML PJME JAO JPvdB JWJB FV.","The authors have the following interests: The Division of Pharmacoepidemiology & Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, employing authors Corinne Klop and Frank de Vries, has received unrestricted funding from the Netherlands Organisation for Health Research and Development (ZonMW), the Dutch Health Care Insurance Board (CVZ), the Royal Dutch Pharmacists Association (KNMP), the private-public funded Top Institute Pharma (www.tipharma.nl, includes cofunding from universities, government, and industry), the EU Innovative Medicines Initiative (IMI), the EU 7th Framework Program (FP7), and the Dutch Ministry of Health and industry (including GlaxoSmithKline, Pfizer, and others); Hubert G.M. Leufkens is a researcher at The WHO Collaborating Centre for Pharmaceutical Policy & Regulation, which receives no direct funding or donations from private parties, including pharma industry. Research funding from public-private partnerships, e.g. IMI, TI Pharma (www.tipharma.nl) is accepted under the condition that no company-specific product or company related study is conducted. The Centre has received unrestricted research funding from public sources, e.g. Netherlands Organisation for Health Research and Development (ZonMW), the Dutch Health Care Insurance Board (CVZ), EU 7th Framework Program (FP7), Dutch Medicines Evaluation Board (MEB), and Dutch Ministry of Health; Jetty A. Overbeek is an employee of the PHARMO Institute. This independent research institute performs financially supported studies for government and related healthcare authorities and several pharmaceutical companies (Abbot, Amgen, Astellas, AstraZeneca, Bayer, BMS, Boehringer Ingelheim, Eli Lilly, GSK, Janssen, Novartis, Novo Nordisk, Pfizer, Sanofi Aventis, Takeda). The authors PMJW, PJME, JPvdB and JWJB declare that they have no conflict of interest. There are no patents, products in development or marketed products to declare. This does not alter the authors adherence to all the PLOS ONE policies on sharing data and materials, as detailed online in the guide for authors.","2015","12","Corinne Klop","CK",8,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA
